How is Foundayo dosed?
The prescribing information’s own escalation schedule, the trials it cites, its boxed warning, and how the first non-peptide oral GLP-1 differs from Rybelsus — every figure attributed to where it was read.
Topic: Reading Foundayo’s FDA prescribing information
Audience: Anyone comparing a dosing schedule against its source
Reading time: 7–9 minutes
Not affiliated with Eli Lilly and Company. Prof. Peptide is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company. Foundayo is a trademark of Eli Lilly and Company. This page reports what Lilly’s own prescribing information and the published trial literature state; it does not sell, ship, or recommend the branded product.
On this page
What Foundayo is — and what it isn’t
Foundayo is not a peptide
Its active ingredient, orforglipron, is a small-molecule GLP-1 receptor agonist — a synthetic, orally bioavailable, non-peptide compound. It acts on the same GLP-1 receptor as peptide drugs like semaglutide and tirzepatide, but by a different binding mode: published research describes orforglipron as a nonpeptide allosteric agonist, where endogenous GLP-1 and the peptide GLP-1 drugs bind primarily to the receptor’s orthosteric pocket instead. Every other compound Prof. Peptide covers is a peptide; this is the first guide on the site for one that isn’t, and that distinction is stated here first so no reader carries an assumption from a peptide guide into this one.
Foundayo is a brand name. The label states it as a GLP-1 receptor agonist indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults who are overweight with at least one weight-related comorbid condition. It was approved by FDA on April 1, 2026, under the Commissioner’s National Priority Voucher pilot program, and is manufactured by Eli Lilly and Company.
The label states Foundayo’s concomitant use with another GLP-1 receptor agonist is not recommended.
What the label specifies
The table below is Foundayo’s recommended dosage as stated in section 2.1 of its prescribing information — Eli Lilly and Company, FOUNDAYO (orforglipron) tablet, film coated, prescribing information, DailyMed setid 8ac446c5-feba-474f-a103-23facb9b5c62, initial U.S. approval 2026.
| Step | Dosage | As specified by the label |
|---|---|---|
| Starting dosage | 0.8 mg once daily | Orally, with or without food. |
| First increase | 2.5 mg once daily | After at least 30 days on the 0.8 mg dosage. |
| Second increase | 5.5 mg once daily | After at least 30 days on the 2.5 mg dosage. |
| Further increases (if needed) | 9 mg, then 14.5 mg, then 17.2 mg once daily | Each after at least 30 days on the current dosage, based on treatment response and tolerability. |
| Maximum dosage | 17.2 mg once daily | The label states this is the maximum recommended dosage. |
The label states: “If a dose is missed, instruct patients to take the dose as soon as possible. Advise patients not to double up the next dose. If 7 or more consecutive doses are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions.”
Dosage forms and strengths (section 3) list film-coated tablets at 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg — the label’s strengths are per-tablet doses, so the label states no reconstitution math anywhere.
How this differs from Rybelsus
Foundayo and Rybelsus are the only two oral GLP-1 receptor agonists with a US label, and they are frequently discussed together — but their take-it rules are not the same, and the label difference traces directly to the molecule difference above.
Foundayo’s label (section 2.1) states it is taken orally once daily, with or without food, setting no fasting window, no water-volume limit, and no waiting period before other food, drink, or medication.
Rybelsus’s own label requires an empty stomach, no more than 4 oz of plain water, and a 30-minute wait before the first food, beverage, or other oral medication of the day — a restriction its label carries because Rybelsus’s active ingredient, semaglutide, is a peptide that needs an absorption enhancer (SNAC) to cross the stomach lining intact, and that enhancer requires an empty, undisturbed stomach to work. Orforglipron is a small enough non-peptide molecule to be orally bioavailable without that enhancer, which is the mechanistic reason its own label carries no equivalent rule. The semaglutide profile covers Rybelsus’s own label in more depth.
What the trials administered
The label’s Clinical Studies section names the trials behind Foundayo’s approved indication. Both trials below grade as attributed against Prof. Peptide’s standing citation convention — each is named in the label itself, with a registry number checkable against ClinicalTrials.gov independent of the label.
Trial 1 (NCT05869903)
Phase 3, randomized, double-blind, placebo-controlled
Arms: 3,127 participants without type 2 diabetes, randomized to placebo or orforglipron at ascending target doses including 17.2 mg once daily.
Endpoint reported: At the 17.2 mg dose: −11.1% body weight change from baseline, versus −2.1% on placebo — a −9 percentage-point difference.
Attributed — cited in the label's Clinical Studies section, with a registry number checkable against ClinicalTrials.gov independent of the label.
Trial 2 (NCT05872620)
Phase 3, randomized, double-blind, placebo-controlled
Arms: 1,613 participants with type 2 diabetes, randomized to placebo or orforglipron at ascending target doses including 17.2 mg once daily.
Endpoint reported: At the 17.2 mg dose: −9.6% body weight change from baseline, versus −2.5% on placebo — a −7.1 percentage-point difference.
Attributed — cited in the label's Clinical Studies section, with a registry number checkable against ClinicalTrials.gov independent of the label.
The label’s warnings and adverse events
Boxed warning: risk of thyroid C-cell tumors
The label states: “In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents. While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined.”
The label states Foundayo is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in patients with known serious hypersensitivity to orforglipron or any of Foundayo’s excipients. The label instructs counseling patients on the potential risk of MTC and its symptoms.
Section 5 of the label lists seven other warnings, discussed elsewhere in the prescribing information: acute pancreatitis, severe gastrointestinal reactions, acute kidney injury due to volume depletion, hypoglycemia, hypersensitivity reactions, diabetic retinopathy complications, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation.
The label states the most common adverse reactions, reported in ≥5% of Foundayo-treated patients, are:
- Nausea
- Constipation
- Diarrhea
- Vomiting
- Dyspepsia
- Abdominal pain
- Headache
- Abdominal distension
- Fatigue
- Eructation
- Gastroesophageal reflux disease
- Flatulence
- Hair loss
The label reports nausea in 10% of placebo-treated patients, versus 26–35% across the Foundayo dosage levels studied.
Research-grade orforglipron
Foundayo’s prescribing information does not mention compounding or research-grade material. Everything above this section describes a prescription drug product, manufactured by Eli Lilly and Company and dispensed by a pharmacy against a prescription.
Research-grade orforglipron, of the kind Prof. Peptide tracks prices for elsewhere on this site, is neither the branded product described above nor a pharmacy-compounded version of it. It is sold labeled for research use, not for human administration, and it is not dispensed against a prescription.
This guide reports Foundayo’s own label. It does not route a reader toward research-grade orforglipron as a substitute for the prescription drug.
FAQ
Is Foundayo a peptide?
What is the starting dose on the Foundayo label?
What is the full titration schedule?
Does Foundayo need to be taken on an empty stomach, like Rybelsus?
What happens if a dose is missed?
Does Foundayo carry a boxed warning?
Is research-grade orforglipron the same as Foundayo?
References
- Eli Lilly and Company. FOUNDAYO (orforglipron) tablet, film coated — prescribing information. DailyMed, setid 8ac446c5-feba-474f-a103-23facb9b5c62, initial U.S. approval 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
- U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. Press Announcements, 2026-04-01. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. PMID 40544435. https://pubmed.ncbi.nlm.nih.gov/40544435/
- ClinicalTrials.gov. A Study of Orforglipron (LY3502970) in Participants Who Have Obesity or Overweight, NCT05869903. https://clinicaltrials.gov/study/NCT05869903
- ClinicalTrials.gov. A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight, NCT05872620. https://clinicaltrials.gov/study/NCT05872620
We may earn commissions from peptide vendor affiliate links.